Smaller device makers put in a muted performance
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
De novo device clearances fall out of fashion
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
Mid cap device makers find rewards in cancer and diabetes
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Zolgensma heads up spate of US approvals
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
Led by Tandem, small-cap medtechs pump up the value in 2018
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Smaller medtechs soar in ’17 but could now be too expensive
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.
